Updates

July 9, 2026 BSE Limited The National Stock Exchange of India Ltd Phiroze Jeejeebhoy Towers, 25th Floor, Dalal Exchange Plaza, Street, Mumbai – 400 001 Bandra Kurla Complex Bandra (E), Mumbai – 400 001 Scrip Code: 524558 Scrip Code: NEULANDLAB; Series: EQ Dear Sir/Madam, Sub: Business Responsibility and Sustainability Report for FY 2025-26 Pursuant to Regulation 34 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations 2015, please find enclosed the Business Responsibility and Sustainability Report for FY 2025-26. The BRSR forms an integral part of the Integrated Annual Report of the Company for the financial year 2025-26. The BRSR is also available on the Company’s website and can be accessed at the following link: Business Responsibility and Sustainability Report for FY 2025-26 This is for your information and records. Thanking you Yours Sincerely, For Neuland Laboratories Limited Sarada Bhamidipati Company Secretary Encl: As above Integrated Annual Report 2025-26 BUSINESS RESPONSIBILITY AND SUSTAINABILITY REPORTING SECTION A: SECTION B: SECTION C: GENERAL MANAGEMENT PRINCIPLE-WISE 2 7 11 DISCLOSURES AND PROCESS PERFORMANCE DISCLOSURES DISCLOSURE PRINCIPLE 1: PRINCIPLE 2: PRINCIPLE 3: BUSINESSES SHOULD BUSINESSES SHOULD BUSINESSES SHOULD CONDUCT AND GOVERN PROVIDE GOODS AND RESPECT AND PROMOTE THEMSELVES WITH INTEGRITY SERVICES IN A MANNER THAT THE WELL-BEING OF ALL AND IN A MANNER THAT IS IS SUSTAINABLE AND SAFE EMPLOYEES, INCLUDING ETHICAL, TRANSPARENT THOSE IN THEIR AND ACCOUNTABLE VALUE CHAINS PRINCIPLE 4: PRINCIPLE 5: PRINCIPLE 6: BUSINESSES SHOULD BUSINESSES SHOULD BUSINESSES SHOULD RESPECT THE INTERESTS OF RESPECT AND PROMOTE RESPECT AND MAKE EFFORTS AND BE RESPONSIVE TO ALL HUMAN RIGHTS TO PROTECT AND RESTORE ITS STAKEHOLDERS THE ENVIRONMENT PRINCIPLE 7: PRINCIPLE 8: PRINCIPLE 9: BUSINESSES, WHEN ENGAGING BUSINESSES SHOULD BUSINESSES SHOULD ENGAGE IN INFLUENCING PUBLIC PROMOTE INCLUSIVE WITH AND PROVIDE VALUE AND REGULATORY POLICY, GROWTH AND TO THEIR CONSUMERS IN A SHOULD DO SO IN A MANNER EQUITABLE DEVELOPMENT RESPONSIBLE MANNER THAT IS RESPONSIBLE AND TRANSPARENT Neuland Laboratories Limited SECTION A: GENERAL DISCLOSURES I. Details of the Entity 1. Corporate Identity Number (CIN) of the Company L85195TG1984PLC004393 2. Name of the Company Neuland Laboratories Limited 3. Year of Incorporation 07/01/1984 4. Registered office address 11th Floor (5th Level), Phoenix IVY Building, Plot No. 573A-III, Road No. 82, Jubilee Hills, Hyderabad, 500033, Telangana 5. Corporate office address 11th Floor (5th Level), Phoenix IVY Building, Plot No. 573A-III, Road No. 82, Jubilee Hills, Hyderabad, 500033, Telangana 6. E-mail id ir@neulandlabs.com 7. Telephone +91 40 67611600 / 700 8. Website www.neulandlabs.com 9. Financial year for which reporting is being done April 1, 2025, to March 31, 2026 10. Name of the Stock Exchange(s) where shares are listed a. BSE Limited b. National Stock Exchange of India Limited 11. Paid-up capital `12,82,98,890/- 12. Name and contact details of the person who may be Ms. Sarada Bhamidipati contacted in case of any queries on the BRSR report Company Secretary & Compliance Officer Tel: +91 40-6761 1600 Email: saradab@neulandlabs.com 13. Reporting boundary Standalone basis 14. Name of assessment or assurance provider BDO India Services Private Limited 15. Type of assessment or assurance obtained Reasonable Assurance for BRSR Core Indicators. II. Products/services 16. Details of business activities S. No. Description of main activity Description of business activity % of turnover of the entity 1 Manufacturing of Active Pharmaceutical Manufacturing of Active 100% Ingredients Pharmaceutical Ingredients 17. Products/services sold by the entity S. No. Product/Service NIC Code % of total turnover contributed 1 Development, manufacturing & sale of Active 21001 100.00% Pharmaceutical Ingredients & Custom Manufacturing Solutions III. Operations 18. Number of locations where plants and/or operations/offices of the entity are situated. Location Number of plants* Number of offices Total National 4* 1 5 International 0 2 2 *The R&D Unit of the Company is included under Number of plants. The Company entered into a lease arrangement for a new R&D location during the FY 2025-26. The facility had not commenced during the reporting period and therefore the site has not been included within the operational reporting boundary. Integrated Annual Report 2025-26 19. Markets served by the entity a. Number of locations – This refers to locations where goods were transported to during the financial year, however the consumption of final product & even customer footprint is larger. Locations Number National (No. of states) 11 International (No. of countries) 59 b. What is the contribution of exports as a percentage of the total turnover of the entity? The company has a global presence with exports accounting for approximately 76% of its revenue. c. A brief on types of customers N euland serves a diversified global customer base across its core business verticals: Generic Drug Substances (GDS), Custom Manufacturing Solutions (CMS), and peptide APIs. The Company caters to pharmaceutical and biotechnology companies across regulated and semi-regulated markets in over 80 countries, including the United States, Europe, Japan, and Latin America. Generic Drug Substances (GDS): T he GDS business primarily serves generic pharmaceutical companies seeking high-quality, regulatory- compliant Active Pharmaceutical Ingredients (APIs). Its customers include large multinational generic companies, regional and domestic pharmaceutical manufacturers, distributors, and companies involved in dossier development and niche product filings. Custom Manufacturing Solutions (CMS): T he CMS business caters to innovator pharmaceutical and biotechnology companies requiring end-to-end API development and manufacturing support. Customers range from emerging biotech firms and mid-sized innovators to large global pharmaceutical companies. Neuland supports these customers across the product lifecycle, from pre-clinical and clinical development to commercial manufacturing and regulatory support. Peptide API Customers: N euland also serves customers requiring peptide synthesis and manufacturing solutions, including companies involved in advanced therapeutics and specialty pharmaceutical products. The Company supports peptide development for clinical and commercial requirements through its expanding peptide manufacturing capabilities. IV. Employees 20. Details as of March 31, 2026 a. Employees and workers (including differently abled) S. Particulars Total (A) Male Female No. (B) % (B/A) No. (C) % (C/A) EMPLOYEES 1. Permanent (D) 2097 1837 87.60% 260 12.40% 2. Other than permanent (E) 374 367 98.13% 7 1.87% 3. Total employees (D + E) 2471 2204 89.19% 267 10.81% WORKERS 1. Permanent (F) 86 86 100.00% 0 0.00% 2. Other than permanent (G) 1324 1234 93.20% 90 6.80% 3. Total workers (F + G) 1410 1320 93.62% 90 6.38% Neuland Laboratories Limited b. Differently abled employees S. No. Particulars Total (A) Male Female No. (B) % (B/A) No. (C) % (C/A) DIFFERENTLY ABLED EMPLOYEES 1. Permanent (D) 1 1 100% 0 0% 2. Other than permanent (E) 0 0 0% 0 0% 3. Total differently abled 1 1 100% 0 0% employees (D + E) DIFFERENTLY ABLED WORKERS 1. Permanent (F) 0 0 0% 0 0% 2. Other than permanent (G) 0 0 0% 0 0% 3. Total differently abled 0 0 0% 0 0% workers (F + G) 21. Participation/inclusion/representation of women Total (A) No. and percentage of females No. (B) % (B/A) Board of Directors 8 1 12.50% Key Management Personnel (other than BoD) 2 1 50.00% 22. Turnover rate for permanent employees FY 2025-26 (%) FY 2024-25 (%) FY 2023-24 (%) Male Female Total Male Female Total Male Female Total Permanent Employees 13.40 16.10 14.30 15.69 25.26 16.81 18.41 18.45 18.42 Permanent Workers 0 0 0 0 0 0 0 0 0 V. Holding, Subsidiary and Associate Companies (including joi [Showing first 8,000 characters — download PDF for full document]